25 results about "Urinary Bladder Cancer" patented technology

The present invention provides methods for treatment of high-risk non-muscle invasive bladder cancer that is unresponsive to BCG therapy by locally administering gemcitabine to the bladder. Also provided herein are kits and articles of manufacture for treating high-risk non-muscle invasive bladder cancer that is unresponsive to BCG.

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

FIELD: urology; oncology.SUBSTANCE: used to diagnose the form of bladder cancer in patients with urothelial carcinoma. Tumor tissue is collected. The expression levels of microRNA miR-26b, miR-146b, miR-183 are determined. The obtained values are substituted into the formula for calculating the probability of muscle-invasive bladder cancer (U). If the Y value is above 0.5, muscle-invasive bladder cancer is diagnosed. If the Y value is equal to or lower than 0.5, non-muscle-invasive cancer is diagnosed.EFFECT: method improves the diagnostic accuracy by assessing the expression level of miR-26b, miR-146b, and miR-183.1 cl, 2 ex

The present invention relates to radiolabeled gemtuzumab ozogamicin antibodies and humanized versions conjugated with the radionuclide astatine 211 The antibody conjugates are used in radiotherapy for the treatment of urothelial cancer, including bladder cancer.

The application belongs to the technical field of pharmacy, and relates to a thiazole compound, a preparation method and application thereof, and a pharmaceutical composition.The thiazole compound is shown in formula (I), is a PRMT5-MTA inhibitor, and can be used for preventing and / or treating PRMT5-mediated diseases, such as ovarian cancer, lung cancer, lymphoma, glioblastoma, colon tumor, melanoma, gastric cancer, pancreatic cancer or bladder cancer.

The application discloses application of NDUFB4 as a target point in preparation of a drug for treating bladder cancer. Single cell analysis results show that NDUFB4 is highly enriched in bladder cancer epithelial cells, and can be used as a key coordinator to participate in the regulation of multiple carcinogenic signal pathways. Through shRNA-mediated gene silencing and CRISPR / Cas9-mediated gene knockout experiments, it is found that NDUFB4 deletion can significantly inhibit the proliferation, migration and invasion ability of bladder cancer cells, and cause a serious bioenergy crisis, and activate the endogenous apoptosis pathway. In a subcutaneous xenotransplant tumor model, it is further verified that NDUFB4 silencing can significantly inhibit tumor growth. The application discloses that NDUFB4 is a key coordinator between mitochondrial high-functionality and carcinogenic signal pathways, and it is suggested that NDUFB4 can become a potential target for bladder cancer treatment.

The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer).

The application discloses a bladder cancer cell segmentation method and device based on urine sediment microscopy and a storage medium; the method comprises the following steps: taking a urine sediment microscopy image as an input image, inputting the input image into a detection model, marking a high-suspected cancer cell area in the input image through the detection model, and generating a boundary box; segmenting the high-suspected cancer cell area in the boundary box through a segmentation model, obtaining a mask of each cancer cell, deleting the corresponding boundary box if the mask is empty or the area ratio is lower than a preset threshold, mapping the effective mask back to the input image, merging all the effective masks, and generating a segmentation result of the cancer cells. The detection model can effectively reduce the processing range of the segmentation model, avoid the waste of computing resources caused by full-image search, and improve the processing speed. The segmentation model can automatically filter out false detection or invalid areas, and ensure the accuracy and reliability of the segmentation result.

The application discloses a biomarker related to bladder cancer and application thereof, the biomarker is tRF-1:28-chrM.Ser-TGA and / or tiRNA-1:34-Glu-CTC-1-M2, which can be used for preparing a bladder cancer early high-risk patient diagnosis and / or prognosis evaluation product, and belongs to the technical field of biological medicine. The biomarker is screened through RNA sequencing, has higher sensitivity and specificity as a biomarker, and is verified through qRT-PCR and ROC curve analysis, and it is proved that tRF-1:28-chrM.Ser-TGA and tiRNA-1:34-Glu-CTC-1-M2 can excellently distinguish bladder cancer patients from normal people, and can be used as an early diagnostic biomarker and a new treatment target of bladder cancer patients, which has great clinical value and practical significance for early clinical diagnosis of bladder cancer, related treatment target evaluation and improvement of the survival rate of patients.

The application relates to the technical field of image processing, in particular to a bladder cancer contour drawing method and system based on ultrasonic images. The method comprises the following steps: acquiring bladder ultrasonic images and contrast images under each view angle; obtaining a muscle layer infiltration depth factor according to the shape, length and surrounding pixel gray scale of blood vessels in each region in the ultrasonic images, and determining a deviation error factor of each region under each view angle; obtaining a pulling error sensitive factor according to the volume change of the bladder cavity, the distance between the tumor region and the texture region of the urinary muscle bundle, the overall tumor displacement direction and the local muscle bundle main direction in each frame of the bladder ultrasonic images under each view angle, and then obtaining the registration error cumulative value of each region under each view angle; and comprehensively obtaining a drawing error coefficient by combining the deviation error factor, the registration error cumulative value and the pulling error sensitive factor, adjusting an initial edge reservation parameter, and obtaining a bladder cancer contour drawing result. The application improves the accuracy of the bladder cancer contour drawing result.

Described herein are treatments and patient selection methods for cancers such as prostate cancer, breast cancer, liver cancer, bladder cancer, and melanoma. The treatment involves administering a RIPK2 inhibitor to a subject. The patient selection involves selecting a patient who has increased copy numbers or expression of both RIPK2 and MYC.

This invention discloses the application of TRIM21-related biopharmaceuticals in the preparation of YME1L1-related products. It reveals the interaction between TRIM21 and YME1L1 and its key regulatory mechanism in the development and progression of bladder cancer. Studies show that TRIM21 specifically binds to the YME1L1 protein through its SPRY domain, mediating K63-linked ubiquitination modification of YME1L1 and thus promoting its protein degradation. Functional experiments confirm that TRIM21 inhibits the proliferation, migration, invasion, and mitochondrial function of bladder cancer cells and induces apoptosis by downregulating YME1L1 protein levels. This invention elucidates for the first time the tumor-suppressive mechanism of the TRIM21-YME1L1 signaling axis in bladder cancer, providing a new molecular marker for the diagnosis and prognostic assessment of bladder cancer, and offering a theoretical basis and intervention strategy for developing anti-tumor drugs targeting the TRIM21 / YME1L1 pathway.

The application relates to the field of biomedical detection technology, in particular to a bladder cancer postoperative recurrence monitoring method based on a ctDNA methylation spectrum, which comprises the following steps: collecting postoperative patient cell-free plasma and extracting circulating tumor DNA; performing bisulfite conversion treatment on the DNA; performing targeted amplification using a multiplex PCR primer group designed for a group of predetermined genomic methylation regions related to recurrence, constructing a sequencing library; performing high-throughput sequencing on the library, obtaining methylation level data of a plurality of CpG sites to form a sample methylation spectrum data matrix; the core of the application is that tumor heterogeneity is overcome through multi-marker combination detection, and a machine learning model is used to integrate multidimensional data to realize precise risk stratification, which has the advantages of non-invasiveness, high sensitivity, high specificity and quantifiable output, and provides an effective tool for individualized follow-up management of bladder cancer postoperation.

This invention discloses a VH032-modified phthalocyanine, its preparation method, and its applications. A chemical synthesis method involving amino and carboxyl coupling is employed. The photosensitizer ZnPc and the Von Hippel-Lindau (VHL) ligand VH032 are linked using either no linker or an alkyl or PEG chain as a linker to construct the VH032-modified phthalocyanine. This drug can degrade VHL after light irradiation and, combined with photodynamic therapy (PDT), efficiently kill tumor cells, achieving a phototoxicity index (PI) of 36397. Utilizing the more active regulation of Cyclin Dependent Kinase 2 / 4 (CDK2 / 4) by VHL in bladder cancer tumor tissue, after light irradiation, this compound exhibits a selectivity index (SI) of 749 for killing bladder cancer cells compared to normal cells, achieving selective killing of tumor cells under light conditions and effectively avoiding the risk of damage to adjacent normal tissues during treatment.

The present disclosure relates to delivering payloads to the interior of a cell. In particular, the present disclosure provides three monoclonal antibodies that bind dystroglycan (DG) on the surface of cells. The antibodies are internalized into endocytic vesicles inside the cells once they are bound to DG. Thus, these antibodies can be used to selectively target and deliver payloads to cells, such as epithelial cells in cancer. The disclosed antibodies bind to DG independent of variable DG glycosylation. The targeted delivery enables selective treatment, imaging, and surveillance of cells in cancer, such as bladder cancer, along with other uses.

The application belongs to the field of biological detection and relates to a kind of establishment and clinical use for bladder cancer prognosis risk marker.The marker is composed of 23 mutant genes of AHNAK2,RYR2,USH2A,DCHS2,BRCA2,RP1L1,FBN2,ZFYVE26,ANK1,NCOR1,F8,WNK1,IGSF10,COL11A1,RANBP2,MED1,FANCM,MYO18B,ZNFX1,MROH2B,AUTS2,CNOT1,COL5A1.The application screens reliable and independent biomarker which can effectively predict the clinical prognosis of bladder patients.Provides a best mutant marker as potential prognostic biomarker and prediction model for combined chemotherapy response of bladder patients.

The application relates to the technical field of marine medicines, and particularly discloses an Aphidicolin diterpenoid compound, a preparation method thereof and application of the Aphidicolin diterpenoid compound in anti-tumor medicines. The application is characterized in that a specific culture medium is used to cultivate a deep-sea derived fungus Botryotinia fuckeliana MCCC 3A00494, and a secondary metabolite Aphidicolin diterpenoid compound is obtained from a fermentation product through various chromatography technologies. Twelve new Aphidicolin diterpenoid compounds are separated, and the Aphidicolin diterpenoid compounds are identified to include nine rare nor-diterpenes. Through experimental research, the separated Aphidicolin diterpenoid compounds have obvious inhibiting effects on a human T24 bladder cancer tumor cell line, and can be used for preparing and developing bladder cancer treatment medicines. On the other hand, the application also provides a lead compound for treating bladder cancer, and has good application and development potential.

Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and / or maintenance therapy.

This invention discloses the application of CALD1 protein in the preparation of drugs for treating bladder cancer, belonging to the field of biomedical technology. The application of CALD1 protein in the preparation of drugs for treating bladder cancer: This invention, through the construction of drug-resistant cell lines using in vivo animal models and combined with clinical sample analysis, first discovered that CALD1 is highly expressed in cisplatin-resistant bladder cancer cells and is associated with poor patient prognosis, demonstrating that CALD1 is a potential novel target for treating cisplatin resistance in bladder cancer, which is beneficial for further research on the mechanism of tumor chemotherapy resistance caused by abnormal activation of CALD1.

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods for treating bladder cancer, methods for determining whether a patient with bladder cancer is likely to respond to treatment comprising a PD-L1 axis-binding antagonist, methods for predicting the response of a patient with bladder cancer to treatment comprising a PD-L1 axis-binding antagonist, and methods for selecting a therapy for a patient with bladder cancer, based on the somatic mutation levels of the genes of the invention (for example, somatic mutation levels in a tumor sample obtained from the patient).

The present invention relates to an isolated targeted delivery system and immune checkpoint modulator for use in a method of treating bladder cancer, wherein the isolated targeted delivery system comprises a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and a pharmaceutically active substance.

A pharmaceutical composition containing triptolide or a derivative thereof, as well as methods of using the composition and methods of manufacturing the composition. The composition can be prepared using thermokinetic compounding and can provide improved properties, such as improved bioavailability. The composition can improve the therapeutic treatment of cancers such as pancreatic cancer, breast cancer, bladder cancer, kidney cancer, ovarian cancer, glioblastoma, or melanoma.

The present invention discloses a bladder cancer detection kit and detection method. The kit includes a DHFR PCR reaction solution, a Twist1 and TSC21 PCR reaction solution, a point mutation positive control, a methylation positive control and a negative control. According to the present invention, by detecting the point mutation of a DHFR gene and the methylation level of a promoter region of TSC21 and Twist1 genes in a sample, the joint detection of gene point mutation and methylation is achieved for determining whether the sample is cancerous. The kit is convenient and simple to operate, high in detection sensitivity and high in specificity, and has a very positive significance in the detection of bladder cancer.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer. The compounds are represented by the following formulaor a pharmaceutically acceptable salt thereof.